NewAmsterdam Pharma N.V. (NAMS)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
24.25
0.58 (2.45%)
At close: Jan 15, 2025, 10:24 AM
Income Statement (Annual)
Get detailed income statement breakdowns, uncovering revenue, expenses, and much more.
Year | FY23 | FY22 | FY21 | FY20 |
Revenue | 12.76M | 95.91M | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a |
Gross Profit | 12.76M | 95.91M | n/a | n/a |
Operating Income | -165.73M | -3.32M | -30.73M | -5.43M |
Interest Income | 10.22M | 268.03K | 361.10K | 344.00K |
Pretax Income | -160.25M | -21.14M | -36.71M | -5.75M |
Net Income | -176.94M | -21.14M | -36.71M | -5.75M |
Selling & General & Admin | 29.77M | 18.22M | 5.27M | 1.38M |
Research & Development | 159.42M | 81.01M | 25.46M | 4.04M |
Other Expenses | n/a | n/a | n/a | n/a |
Operating Expenses | 197.06M | 116.78M | 36.35M | 5.40M |
Interest Expense | 6.80M | n/a | n/a | n/a |
Selling & Marketing Expenses | 4.06M | 1.60M | 858.39K | 11.00K |
Cost & Expenses | 183.23M | 116.78M | 36.35M | 5.40M |
Income Tax | 27.00K | n/a | n/a | n/a |
Shares Outstanding (Basic) | 82.16M | 18.97M | 17.75M | 17.75M |
Shares Outstanding (Diluted) | 82.16M | 18.97M | 17.75M | 17.75M |
EPS (Basic) | -2.15 | -1.11 | -3.34 | -1.15 |
EPS (Diluted) | -2.15 | -1.11 | -3.34 | -1.15 |
EBITDA | -176.86M | -3.31M | -30.73M | -5.43M |
Depreciation & Amortization | 49.00K | 8.40K | 4.39K | 1K |